98%
921
2 minutes
20
Identifying an epidermal growth factor receptor (EGFR) mutation is important because EGFR tyrosine kinase inhibitors are the first-line treatment of choice for patients with EGFR mutation-positive lung adenocarcinomas (LUAC). This study is aimed at developing and validating a radiomics-based machine learning (ML) approach to identify EGFR mutations in patients with LUAC. We retrospectively collected data from 201 patients with positive EGFR mutation LUAC (140 in the training cohort and 61 in the validation cohort). We extracted 1316 radiomics features from preprocessed CT images and selected 14 radiomics features and 1 clinical feature which were most relevant to mutations through filter method. Subsequently, we built models using 7 ML approaches and established the receiver operating characteristic (ROC) curve to assess the discriminating performance of these models. In terms of predicting EGFR mutation, the model derived from radiomics features and combined models (radiomics features and relevant clinical factors) had an AUC of 0.79 (95% confidence interval (CI): 0.77-0.82), 0.86 (0.87-0.88), respectively. Our study offers a radiomics-based ML model using filter methods to detect the EGFR mutation in patients with LUAC. This convenient and low-cost method may be of help to noninvasively identify patients before obtaining tumor sample for molecule testing.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9107363 | PMC |
http://dx.doi.org/10.1155/2022/2056837 | DOI Listing |
Comput Biol Chem
September 2025
Faculty of Health Sciences, University of Macau, Avenida de Universidade, Taipa, Macao Special Administrative Region of China. Electronic address:
With the advancements of next-generation sequencing, publicly available pharmacogenomic datasets from cancer cell lines provide a handle for developing predictive models of drug responses and identifying associated biomarkers. However, many currently available predictive models are often just used as black boxes, lacking meaningful biological interpretations. In this study, we made use of open-source drug response data from cancer cell lines, in conjunction with KEGG pathway information, to develop sparse neural networks, K-net, enabling the prediction of drug response in EGFR signaling pathways and the identification of key biomarkers.
View Article and Find Full Text PDFJ Thorac Oncol
September 2025
Department of Internal Medicine, Section of Medical Oncology and Hematology, Yale School of Medicine, New Haven, Connecticut; Yale Cancer Center, New Haven, Connecticut.
Cancer Treat Res Commun
August 2025
Department of Diagnostic Pathology, Saitama Medical University International Medical Center, Saitama, Japan.
Objectives: Although radiologic ground-glass opacity (GGO) components are associated with favorable prognosis, limited evidence supports the prognostic significance of corresponding histologic lepidic components. This study aimed to evaluate the prognostic value of lepidic components in patients with surgically resected invasive non-mucinous lung adenocarcinoma at pathologic (p-) stages I to IIIA.
Materials And Methods: We retrospectively analyzed 352 patients who underwent resection for invasive non-mucinous adenocarcinoma between 2012 and 2016.
ESMO Open
September 2025
Department of Pulmonary and Critical Care Medicine, Fuzong Clinical Medical College of Fujian Medical University & The 900th Hospital of Joint Logistic Support Force, PLA, Fuzhou, China. Electronic address:
Background: The clinical impact of rare epidermal growth factor receptor (EGFR) exon 19 insertion-deletion (19delins) variants on tyrosine kinase inhibitor (TKI) efficacy remains poorly characterized. We updated 5-year outcomes to evaluate long-term survival and optimal treatment strategies in advanced lung adenocarcinoma (LUAD) patients harboring these mutations.
Materials And Methods: In this multicenter prospective study, 36 treatment-naive advanced LUAD patients with EGFR 19delins mutations received first-generation (n = 26) or third-generation TKIs (n = 10).
J Clin Neurosci
September 2025
Department of Neurosurgery, Rigshospitalet, Copenhagen, Denmark; Department of Clinical Medicine, Copenhagen University, Copenhagen, Denmark; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden. Electronic address:
Background: Meningiomas exhibit considerable phenotypic variation within each WHO grade, thus additional markers are needed to identify prognostically relevant subgroups and optimize long-term management. Among biomarkers, genetic signatures correlate with prognoses. High Ki-67 proliferation indices and TERT promotor mutations and loss of CDKNA are known prognostic markers.
View Article and Find Full Text PDF